The Nasdaq Composite ended October 1, 2026 at 26,871.60, while Mattel, Synaptics, MaxLinear and Silicon Labs finished higher.
Spotrate
Market News
Capital markets news reporting across technology, energy, healthcare, and global macro sectors.
QSE Appoints Joseph Hall as Cybersecurity Leaders Shape Enterprise Protection
QSE appoints cybersecurity veteran Joseph Hall as it targets enterprise and government opportunities. Sector context includes Palo Alto Networks, CrowdStrike, Fortinet and Zscaler.
VisionWave Expands Global Defense Trials: AVAV, Kratos and Elbit
VisionWave expands international customer evaluations for autonomous defense systems. AeroVironment, Kratos and Elbit provide context on the path from demonstrations to procurement.
Amkor Gains 1.8% as Apple, Microsoft and Nvidia Slide
Amkor rose 1.81% on 29 September, outperforming Apple, Microsoft and Nvidia as US stock indexes edged lower.
US Treasury Yield Index Reaches 5%: What Higher Rates Mean Across Market Sectors
A 5% yield across a US Treasury index raises the benchmark for capital, testing housing, technology, smaller companies and indebted issuers while offering fresh income to savers and insurers.
ONCY’s REO 033 Colorectal Cancer Trial Advances. How Its Catalyst Compares With Roche and Novartis
Oncolytics says nearly all planned REO 033 sites are active and expects a Part A interim update by year-end. We examine its earlier REO 022 signal and the distinct oncology exposure of Roche and Novartis.
Fuse Oncology Expands FuseRx Workflow Across Radiation Oncology Care Team
Fuse Oncology plans to add physicists, dosimetrists, therapists and nurses to its FuseRx workflow, building on its physician-focused launch and a University of Michigan planning tool. The company will demonstrate the expanded roles at ASTRO 2026.
iA Financial Shares Clear a Key Technical Level as Investors Weigh the Broader Business Story
iA Financial shares have moved above a widely followed 200-day moving average, putting technical momentum in focus. Spotrate examines what the signal says—and does not say—alongside the company’s broader corporate story.
Akeso’s ESMO Pipeline Push Puts Ivonescimab’s Commercial Potential Under the Microscope
Akeso heads toward ESMO 2026 with nearly 30 bispecific-antibody studies, expanding commercial sales and multiple Phase III readouts. The next test is whether clinical momentum can translate into broader regulatory and commercial execution.
Fortuna Mining Q2 Results Put Cash Flow and Cost Discipline in Focus Across TSX Gold Peers
Fortuna Mining’s Q2 2026 results showed strong cash generation and a 63% adjusted EBITDA margin, while management expects costs to ease in the second half. Spotrate compares Fortuna with Agnico Eagle, Kinross and B2Gold across production, AISC, earnings and free cash flow.
